1356 studies found for:    VEGF
Show Display Options
Rank Status Study
1 Recruiting Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy
Condition: Diabetic Macular Edema
Intervention:
2 Enrolling by invitation Vascular Endothelial Growth Factor Levels in Ectopic Pregnancy
Condition: Complication Following Ectopic Pregnancy
Intervention:
3 Active, not recruiting VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC)
Condition: Extrahepatic Cholangiocarcinoma
Intervention: Procedure: surgical treatment
4 Unknown  Prospective Randomized Trial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
Condition: Exudative Age-related Macular Degeneration
Interventions: Drug: 24GyE proton and Anti-VEGF;   Drug: 16GyE and anti-VEGF;   Drug: Sham Irradiation and anti-VEGF
5 Completed
Has Results
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
6 Unknown  Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?
Conditions: Choroidal Neovascularization;   Age-Related Macular Degeneration
Intervention: Genetic: VEGF genotyping
7 Completed
Has Results
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
Condition: Exudative Age-related Macular Degeneration.
Interventions: Dietary Supplement: Anti-VEGF plus AREDS-2;   Dietary Supplement: Anti-VEGF plus AREDS-1
8 Recruiting UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-VEGF Effects in Patients With neovascuLar AMD
Condition: Neovacular Age-related Macular Degeneration
Intervention: Procedure: VEGF level assessment
9 Completed Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention: Drug: VEGF Trap-Eye
10 Withdrawn Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
Conditions: Glioma;   Meningioma
Intervention: Procedure: Blood test
11 Unknown  Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
Condition: Wet AMD
Intervention:
12 Completed
Has Results
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
Condition: Macular Degeneration
Interventions: Biological: ranibizumab;   Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
13 Completed
Has Results
VEGF Trap in Treating Patients With Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Intervention: Biological: ziv-aflibercept
14 Completed VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: docetaxel;   Biological: ziv-aflibercept;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Completed Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial
Condition: Coronary Artery Disease
Intervention: Genetic: intramyocardial injection of VEGF-A165/bFGF:placebo plasmid
16 Withdrawn A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Conditions: Carcinoma, Renal Cell;   Glioblastoma;   Carcinoma, Hepatocellular
Interventions: Drug: Crizotinib plus VEGF inhibitor combinations;   Drug: Crizotinib plus axitinib;   Drug: Crizotinib plus sunitinib;   Drug: Crizotinib plus bevacizumab;   Drug: Crizotinib plus sorafenib
17 Active, not recruiting VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway
Condition: Hepatocellular Carcinoma
Intervention: Procedure: surgical treatment
18 Recruiting EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction
Conditions: Pre-eclampsia;   Intra-uterine Growth Retardation
Intervention: Other: blood sample and doppler Ultrasound of uterine arteries
19 Completed Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
Condition: Macular Degeneration
Intervention: Drug: VEGF Trap
20 Terminated TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection
Conditions: Neovascular Age Related Macular Degeneration (AMD);   Open Angle Glaucoma
Interventions: Procedure: Intraocular anti-VEGF injection;   Device: SENSIMED Triggerfish

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years